Drug profile · INN
landiolol hydrochloride
RAPIBLYK
landiolol hydrochloride (RAPIBLYK) is a beta-1 adrenergic receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — landiolol hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
landiolol hydrochloride (RAPIBLYK) is a beta-1 adrenergic receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is landiolol hydrochloride?
landiolol hydrochloride (RAPIBLYK) is a beta-1 adrenergic receptor antagonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for landiolol hydrochloride?
RAPIBLYK is a marketed brand name for landiolol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of landiolol hydrochloride?
landiolol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.